Feagan BG, et al. - A post-hoc analysis of data from phase 3, randomized, controlled trials was performed to examine the time course of clinical response to vedolizumab in patients with inflammatory bowel diseases who were and were not previously treated with tumor necrosis factor (TNF) antagonists. Multivariate logistic regression analysis was performed to identify factors associated with an early response (at week 2). The findings from the present study suggested that vedolizumab significantly improved patient-reported symptoms of ulcerative colitis (UC) and Crohn’s disease (CD) as early as week 2 of treatment, continuing through the first 6 weeks—particularly when given as first-line biologic therapy.